Copper IUD: Clinical Overview
Indications
The copper IUD (Cu-IUD) is indicated for any woman seeking highly effective, long-term, non-hormonal contraception, including nulliparous women, adolescents, and those with contraindications to hormonal methods. 1, 2
Key indications include:
- Primary contraception for up to 10 years 3, 4
- Emergency contraception up to 5 days after unprotected intercourse (or up to 5 days after ovulation if timing can be estimated) 2
- First-line contraceptive for women with history of venous thromboembolism, pulmonary embolism, or coronary events 5
- Safe for breastfeeding women and those with diabetes or HIV infection 5
The outdated notion that IUDs are only for parous women in monogamous relationships should be abandoned—current guidelines explicitly support use in nulliparous women and adolescents 1, 4.
Pre-Insertion Requirements
No pelvic exam, STI screening, or cervical cancer screening is required before IUD insertion if these are not otherwise due—the Cu-IUD can be placed at any time during the menstrual cycle as long as pregnancy is reasonably excluded. 1, 2
Essential requirements (Class A):
- Pregnancy exclusion (clinical assessment)
- Informed consent 2
Not required for safe insertion (Class C):
- Routine pelvic examination (unless clinically indicated)
- Routine STI screening (though recommended if risk factors present)
- Specific timing in menstrual cycle 2, 4
Routine antibiotic prophylaxis is not beneficial and should not be used. 4, 5 However, if active STI is diagnosed, treat before insertion and wait at least 3 months after resolution 4.
Insertion Technique
Perform a bimanual examination immediately before insertion to determine uterine position and sound the uterus to measure cavity depth. 3
Pain Management Protocol
Offer naproxen 500-550 mg orally 1 hour before the procedure (or 2 over-the-counter naproxen sodium tablets = 440 mg) taken with food. 2 Ketorolac 20 mg orally is an alternative. Other NSAIDs can be substituted if naproxen is unavailable.
Additional recommendations:
- Counsel patients to eat a light meal and drink water beforehand 2
- Prepare patients for 3 distinct sensation points: cervical stabilization, uterine sounding, and IUD insertion 2
- Have patient rest briefly post-insertion if experiencing discomfort or dizziness 2
- Consider support person or arranged transportation home 2
Do NOT use misoprostol—it provides no benefit for IUD insertion. 4
Timing Considerations
- Can insert at any point in menstrual cycle if not pregnant 2, 4
- Immediate postpartum insertion (vaginal or cesarean) is possible but has higher expulsion rates 4
- Avoid insertion within 4-6 weeks postpartum due to increased perforation risk 5
- Can insert immediately post-abortion (though expulsion risk higher) 5
Technical Steps
- Bimanual exam to assess uterine position
- Insert speculum and visualize cervix
- Apply tenaculum to stabilize cervix (first sensation point)
- Sound uterus to measure depth (second sensation point)
- Insert IUD per manufacturer protocol (third sensation point)
- Cut strings to appropriate length (allowing patient self-checks) 3
Uterine perforation occurs in 0.6-16 per 1,000 insertions—risk is higher with postpartum/post-abortion insertion. 5
Side Effects and Management
Expected Side Effects
The primary side effect of Cu-IUD is increased menstrual bleeding and dysmenorrhea, which may persist even with long-term use. 4, 5
- Heavier menstrual bleeding occurs in most users 5, 6
- Dysmenorrhea requiring analgesia: 72% in nulliparous vs 47% in parous women 6
- Pain at insertion: higher in nulliparous (VAS 6.5±2.4) vs parous (3.9±2.2) 6
Managing Bleeding Irregularities
For Cu-IUD users with spotting, light bleeding, or heavy/prolonged bleeding: offer NSAIDs for 5-7 days. 1 This is the only evidence-based treatment option for Cu-IUD-related bleeding.
If patient desires removal at any time, remove the device immediately, offer counseling on alternatives, and initiate another method if desired 1.
Complications
Expulsion occurs in 5-10% within 5 years, with recurrence in 30% of affected women. 5 Expulsion rates: 12.2% in nulliparous vs 3.5% in parous at 6 months 6.
Pelvic inflammatory disease (PID) risk is slightly elevated only in the first 3 months post-insertion (approximately 6 cases per 1,000 woman-years), particularly with pre-existing asymptomatic Chlamydia. 5
Problems at insertion (difficult insertion, pain, bleeding, syncope): <1.5% overall 5
Pregnancy with IUD in Place
If pregnancy occurs with Cu-IUD in place, remove the device if the strings are visible—this improves pregnancy outcomes. 5
- Approximately 25% of intrauterine pregnancies result in live birth if IUD left in place
- Approximately 90% result in live birth if IUD removed 5
- About 1 in 20 pregnancies with IUD in situ are ectopic 5
- Ectopic pregnancies are actually rarer in IUD users than in women using no contraception 5
Contraindications
Absolute contraindications:
- Current pregnancy
- Active pelvic infection or STI (defer insertion until treated and resolved for ≥3 months) 4, 5
- Unexplained vaginal bleeding (postpone until evaluated) 5
Relative considerations:
- Uterine anomalies that distort cavity
- Current PID (see management below)
Removal Criteria
Remove Cu-IUD when:
- Patient requests removal for any reason 1
- Device expiration (10 years for Cu-IUD) 3, 4
- Pregnancy occurs (if strings visible) 5
- Complications develop (perforation, severe infection)
If PID is diagnosed in a Cu-IUD user, the device can remain in place during antibiotic treatment—removal is not mandatory. 1 However, if symptoms do not improve with appropriate antibiotics, consider removal.
Efficacy
Cu-IUD effectiveness: approximately 6 pregnancies per 1,000 woman-years, comparable to correctly-used combined oral contraceptives but superior to typical oral contraceptive use. 5, 7
The TCu380A (380 mm² copper surface area) is more effective than devices with smaller copper surface areas 7. Three-year cumulative pregnancy rate for modern copper IUDs: approximately 4.8% 8.
Continuation Rates
Six-month continuation rate: 92.8% in nulliparous and 83.4% in parous women (no significant difference). 6 Satisfaction rates are high and comparable between nulliparous (89% satisfied/very satisfied) and parous women (97%) 6.